DexCom, Inc. $DXCM Holdings Raised by Nissay Asset Management Corp Japan

Nissay Asset Management Corp Japan increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 6.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 115,276 shares of the medical device company’s stock after purchasing an additional 6,976 shares during the quarter. Nissay Asset Management Corp Japan’s holdings in DexCom were worth $7,764,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DXCM. Norges Bank acquired a new position in DexCom during the 4th quarter valued at about $483,356,000. AQR Capital Management LLC lifted its stake in shares of DexCom by 597.8% in the 4th quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock worth $205,932,000 after acquiring an additional 2,658,158 shares during the period. Legal & General Group Plc acquired a new stake in shares of DexCom in the 2nd quarter worth approximately $173,237,000. Deutsche Bank AG bought a new position in shares of DexCom in the second quarter valued at approximately $164,035,000. Finally, Employees Provident Fund Board bought a new position in shares of DexCom in the fourth quarter valued at approximately $145,352,000. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Deutsche Bank Aktiengesellschaft started coverage on DexCom in a report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 target price on the stock. Citigroup reaffirmed a “buy” rating and set a $88.00 price target (up from $84.00) on shares of DexCom in a research note on Friday, July 31st. Benchmark lifted their price target on DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Barclays reissued an “underweight” rating and issued a $64.00 price objective (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Finally, Bank of America cut their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a report on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

Insider Buying and Selling

In other news, insider Kevin R. Sayer sold 26,756 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the completion of the sale, the insider owned 328,970 shares in the company, valued at approximately $25,106,990.40. This represents a 7.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the sale, the director directly owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 75,600 shares of company stock valued at $5,673,342 in the last three months. Insiders own 0.28% of the company’s stock.

DexCom Price Performance

NASDAQ DXCM opened at $90.82 on Monday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The company’s 50 day simple moving average is $79.21 and its 200 day simple moving average is $71.61. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.59. The company has a market capitalization of $34.27 billion, a P/E ratio of 35.90, a PEG ratio of 1.53 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period last year, the firm posted $0.48 earnings per share. Equities research analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.